ImmunoPrecise Antibodies Ltd (IPA)

[RNsidersbuying]

IPATF .57 - IPA Awarded Grant Focused on Coronavirus and Other Emerging Pathogens

FARGO, ND , April 24, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), is pleased to announce that the state of North Dakota has awarded a Bioscience Innovation Grant totalling US$75,000 for the enhancement of a novel platform for rapidly developing treatments for COVID-19 and other emerging pathogens.

"Advances in bioscience have already transformed many sectors including agriculture and medicine," state Agriculture Commissioner Doug Goehring said. "These grants will help North Dakota stay on the forefront of bioscience innovation."

The Company reports that this grant was the first application of many to be submitted by IPA over the next several months.

"ImmunoPrecise is in the process of applying for both state and federal grants to support the development of a treatment for COVID-19 using our PolyTopeTM mAb Therapy," stated Jennifer Bath , IPA President and CEO. "We turned first to the State of North Dakota , given their strong history of support for Biotechnology and Innovation. It is with gratitude we accept the ND Bioscience Innovation Grant and we are confident we can leverage this funding, along with our research advances, to continue to build on our current successes."

Furthermore, the company is also pleased to announce that that it has been approved for a US$209,000 loan under the Payroll Protection Program ("PPP") administered by the U.S. Small Business Administration.

https://finance.yahoo.com/news/immunoprecise-updates-state-federal-funding-172600570.html